| abstract |
Compounds of formula I: <IMAGE> (I) in which: n=1-4; R represents hydrogen, halogen, alkyl, hydroxyl or alkoxy, R1 represents a radical -NHCOR2 (A1); (in which R2 represents alkyl, cycloalkyl, phenyl optionally substituted-, -O-alkyl, 3-pyridyl, 2-pyrrolyl, quinolyl, 1-isoquinolyl, 2-thienyl or 3-indolyl); a radical of -NHSO2R3 (A2) (in which R3 represents alkyl, cycloalkyl or phenyl optionally substituted); a radical -NHCONHR4 (A3) (in which R4 represents alkyl or phenyl-optionally substituted); a phthalimido radical (A4); an o-sulfobenzoic imido radical (A5); a di(benzoyl)amino radical (A6) optionally substituted; a radical of formula A7: <IMAGE> (A7) (in which R5 represents carbamoyl, cyano, carboxy or alkoxycarbonyl); or a radical of formula A8: <IMAGE> (A8) their stereoisomers and their addition salts with a pharamaceutically-acceptable inorganic or organic acid, are disclosed to be useful as 5-HT1A receptor ligands and accordingly as the active principle in medicinal products containing the same. |